Ask AI
ProCE Banner Activity

NATALEE: Outcomes by Menopausal Status and Age From a Phase III Trial of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With HR+/HER2- EBC 

Conference Coverage
Slideset

Phase III NATALEE showed improved survival benefits with ribociclib plus NSAI regardless of menopausal status and age vs NSAI alone in patients with stage II/III HR+/HER2- early breast cancer at risk of recurrence.

Released: June 04, 2025

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.